

Information For the User
ilaprazole IP (10 mg EC) + Domperidone IP (30 mg SR) Capsule

Ilapprime DSR Capsule

Ilapprime DSR Capsule

Composition:

Each hard gelatin capsule contains:

- **Ilaprazole IP** (Enteric Coated) ... 10 mg
- **Domperidone IP** (Sustained Release) ... 30 mg
- **Excipients** ... q.s.

Dosage Form:

Capsule

Therapeutic Category:

Proton Pump Inhibitor (PPI) + Prokinetic Agent – For Acid Peptic Disorders

Pharmacology & Mechanism of Action:

Ilaprazole is a proton pump inhibitor that irreversibly inhibits H^+/K^+ -ATPase in the gastric parietal cells, reducing gastric acid secretion. Domperidone is a dopamine D2 receptor antagonist with prokinetic properties, enhancing gastrointestinal motility and accelerating gastric emptying. The combination provides effective relief from acid-related gastrointestinal disorders and associated symptoms like nausea and vomiting.

Indications:

- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Dyspepsia with delayed gastric emptying
- Nausea and vomiting associated with acid-related disorders
- Zollinger-Ellison syndrome (as adjunct therapy)

Dosage & Administration:

- **Adults:** One capsule once daily, preferably 30 minutes before meals, or as prescribed by the physician
- Swallow the capsule whole; do not crush or chew
- Adjust dose based on clinical response and tolerability

Contraindications:

- Hypersensitivity to ilaprazole, domperidone, or any excipients
- Patients with prolactin-dependent tumors
- Concomitant use with drugs that prolong QT interval or CYP3A4 inhibitors

Warnings & Precautions:

- Use with caution in patients with hepatic impairment
- Avoid use in patients with severe cardiac disorders
- Monitor for extrapyramidal symptoms in sensitive individuals
- Not recommended in pregnancy and lactation unless prescribed

Adverse Effects:

- Common: Headache, dry mouth, mild gastrointestinal discomfort
- Rare: Dizziness, galactorrhea, menstrual irregularities
- Cardiac: QT prolongation in predisposed patients

Drug Interactions:

- CYP3A4 inhibitors may increase domperidone levels
- Concomitant use with other QT-prolonging agents should be avoided
- Antacids do not affect absorption significantly

Overdose:

- Symptoms: Severe nausea, vomiting, dizziness, arrhythmias
- Treatment: Supportive and symptomatic care

Storage:

Store below 25°C in a cool, dry place
Protect from light and moisture
Keep out of reach of children

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,
Panchkula-134113

TM: Trademark Applied for